What do systematic reviews say?

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

Temsirolimus may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  HR 0.74 [0.6, 0.91]
  1 study · 416 participants
  Low

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

Temsirolimus probably leads to lower overall survival survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (moderate certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  HR 0.78 [0.63, 0.97]
  1 study · 416 participants
  Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

Temsirolimus may leads to lower serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  RR 0.86 [0.76, 0.97]
  1 study · 408 participants
  Low

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 401 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Temsirolimus + IFN‐α may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  HR 0.76 [0.62, 0.93]
  1 study · 417 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Temsirolimus + IFN‐α showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  HR 0.93 [0.75, 1.15]
  1 study · 417 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Temsirolimus + IFN‐α may leads to higher serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  RR 1.12 [1.02, 1.22]
  1 study · 408 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 394 participants
  Low

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Temsirolimus + bevacizumab showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  HR 1.1 [0.9, 1.34]
  1 study · 791 participants
  Low

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Temsirolimus + bevacizumab showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (moderate certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  HR 1.08 [0.9, 1.3]
  1 study · 791 participants
  Moderate

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Temsirolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  RR 1.05 [0.98, 1.13]
  1 study · 784 participants
  Low

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found